Stockreport

Orion's phase 2 study of ODM-105 in insomnia did not meet primary goal [Yahoo! Finance]

ORION CORP NEW UNSP/ADR  (ORINY) 
PDF Orion's phase 2 study of ODM-105 in insomnia did not meet primary goal Orion to discontinue development of ODM-105 for insomnia. ODM-105 (tasipimidine) was well tol [Read more]